Rationing Antiretroviral Therapy in Africa -- Treating Too Few, Too Late

doi:10.1056/NEJMp0902820

GLOBAL HEALTH

Volume 360:1808-1810		April 30, 2009		Number 18

Rationing Antiretroviral Therapy in Africa — Treating Too Few, Too Late

Nathan Ford, D.H.A., Edward Mills, Ph.D., and Alexandra Calmy, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

Interactive Graphic

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

Related Article
by Kitahata, M. M.

PubMed Citation

The past 6 years have seen striking advances in access to antiretroviraltherapy in Africa. From 2002 onward, the international driveto scale up antiretroviral treatment gained considerable momentum,most notably with the establishment of the Global Fund to FightAIDS, Tuberculosis, and Malaria, the "3 by 5" Initiative ofthe World Health Organization (WHO), and the U.S. President'sEmergency Plan for AIDS Relief (PEPFAR). Today, an estimated3 million people in the developing world are receiving antiretroviraltherapy.

The momentum has now begun to wane, with various groups arguingthat the focus on AIDS has had its day and . . . [Full Text of this Article]

Source Information

Mr. Ford is the head of the medical unit of Médecins sans Frontières (MSF), Cape Town, and a research associate at the School of Public Health and Family Medicine, University of Cape Town — both in Cape Town, South Africa. Dr. Mills holds a Canada Research Chair in Global Health, Faculty of Health Sciences, University of Ottawa, Ottawa. Dr. Calmy is a physician in the HIV Unit, Infectious Disease Services, Geneva University Hospital, and an HIV consultant for the MSF Access Campaign, MSF International — both in Geneva.